GlassScriptPhysician profile
Jeffrey C Wolkowicz
NPI 1952315749
$6,880.71
in general payments reported to CMS, 2019-2025
25 companies · $1,673 in 2025
The $1,673 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.99 · 2020: $852 · 2021: $1,088 · 2022: $928 · 2023: $1,209 · 2024: $1,041 · 2025: $1,673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,918 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,917.76 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,503.72 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,174.30 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $604.88 | 2019-2025 | Ofev, Spiriva, Jascayd |
| Inspire Medical Systems, INC. | $302.89 | 2024-2025 | Inspire |
| Genzyme Corporation | $179.84 | 2021-2025 | |
| Mylan Specialty L.P. | $126.03 | 2020-2023 | Yupelri |
| Insmed, INC. | $118.41 | 2024-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $109.16 | 2024-2025 | Dupixent |
| Philips North America LLC | $96.45 | 2020-2023 | |
| Watermark Medical, INC. | $90.07 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $83.11 | 2020-2021 | |
| Verona Pharma, INC. | $77.39 | 2025 | Ohtuvayre |
| Amgen INC. | $67.52 | 2024-2025 | Tezspire |
| Grifols USA, LLC | $66.60 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $42.79 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $29.88 | 2025 | |
| Mallinckrodt Hospital Products INC. | $29.83 | 2020 | |
| 3b Medical, INC. | $29.18 | 2024 | Luna |
| Actelion Pharmaceuticals US, INC. | $23.08 | 2022 | |
| Pulmonx Corporation | $23.07 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Ambu INC. | $22.81 | 2024 | |
| Inogen, INC. | $22.15 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Genentech USA, INC. | $19.62 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.36 | 2020 | |
| Electromed, INC. | $18.57 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Wolkowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.